Urine CrossLaps® (CTX-I) EIA 品牌Immunoassay Systems | IDS

Unique Features

• Management of Postmenopausal Osteoporosis
• Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
• Increase patient motivation and compliance
• Assessment of Bone Resorption in patients
• With metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy
• Receiving prolonged glucocorticoid therapy
• A complete clinical assay  panel supporting bone disease management

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone.

During renewal of the skeleton, Type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can be measured by Urine CrossLaps® (CTX-I) EIA as has been reported as useful for follow up of anti-resorptive treatment of patients with metabolic bone diseases 1, 2, 3.

Buclin T et al., Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002 Aug;17(8):1478-85.

Garnero P. et al., Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int (1998); 8: 563-569.

Nagase S et al., Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women. J Bone Miner Metab. 2014 Jan 24.